Literature DB >> 7695264

Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice.

K Y Hostetler1, D D Richman, C N Sridhar, P L Felgner, J Felgner, J Ricci, M F Gardner, D W Selleseth, M N Ellis.   

Abstract

During the early stages of human immunodeficiency virus (HIV) infection, although symptoms are absent and viral replication in peripheral blood mononuclear cells is low, substantial levels of HIV replication can be documented in lymphoid tissue [G. Pantaleo, C. Graziosi, J.F. Demarest, L. Butini, M. Montroni, C.H. Fox, J.M. Orenstein, D.P. Kotler, and A.S. Fauci, Nature (London) 362:355-358, 1993, and J. Embretsen, M. Zupancic, J.L. Ribas, A. Burke, P. Racz, K. Tenner-Tacz, and A.T. Haase, Nature (London) 362:359-362, 1993]. This observation suggests that earlier treatment of HIV infection may be indicated and that strategies for enhancing drug targeting to the lymphoid tissue reservoris of HIV infection may be beneficial. To address this issue, we synthesized dioleoylphosphatidyl-ddC (DOP-ddC) and dipalmitoylphosphatidyl-3'-azido-3'-deoxythymidine (DPP-AZT), phospholipid prodrugs which form lipid bilayers and which are readily incorporated into liposomes. The anti-HIV activity of DOP-ddC was similar to that of ddC in HIV type 1-infected HT4-6C cells, but DPP-AZT was considerably less active than AZT in HT4-6C cells. Liposomes containing DOP-[3H]ddC or DPP-[3H]AZT administered intraperitoneally to mice produced greater levels of total radioactivity over time in plasma, spleen, and lymphoid tissue relative to the results with [3H]ddC and [3H]AZT, respectively. DPP-AZT administered intraperitoneally in liposomes as a single daily dose to mice infected with Rauscher leukemia virus prevented increased spleen weight and reverse transcriptase levels in serum with a dose-response roughly comparable to that of AZT given continuously in the drinking water. DOP-ddC, DPP-AZT, and lipid conjugates of other antiretroviral nucleosides may provide higher levels of drug over time in plasma and in lymph nodes and spleen, important reservoirs of HIV infection, and may represent an interesting alternative approach to antiviral nucleoside treatment of AIDS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695264      PMCID: PMC188287          DOI: 10.1128/AAC.38.12.2792

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Vesicles of variable sizes produced by a rapid extrusion procedure.

Authors:  L D Mayer; M J Hope; P R Cullis
Journal:  Biochim Biophys Acta       Date:  1986-06-13

2.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

3.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.

Authors:  R E Chaisson; M D Leuther; J P Allain; S Nusinoff-Lehrman; G S Boone; D Feigal; P Volberding
Journal:  Arch Intern Med       Date:  1988-10

5.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

6.  Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice.

Authors:  K Y Hostetler; B E Korba; C N Sridhar; M F Gardner
Journal:  Antiviral Res       Date:  1994-05       Impact factor: 5.970

7.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.

Authors:  J Balzarini; R Pauwels; M Baba; P Herdewijn; E de Clercq; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1988-03-01       Impact factor: 5.858

10.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

View more
  3 in total

1.  Design and synthesis of nucleolipids as possible activated precursors for oligomer formation via intramolecular catalysis: stability study and supramolecular organization.

Authors:  Kishore Lingam Gangadhara; Puneet Srivastava; Jef Rozenski; Henri-Philippe Mattelaer; Volker Leen; Wim Dehaen; Johan Hofkens; Eveline Lescrinier; Piet Herdewijn
Journal:  J Syst Chem       Date:  2014-12-09

Review 2.  The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold.

Authors:  Katherine L Seley-Radtke; Mary K Yates
Journal:  Antiviral Res       Date:  2018-04-10       Impact factor: 10.103

Review 3.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.